Eritril

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Eritril

Property Description
Active ingredient Enalapril (as Enalapril maleate)
Form Tablet (Oral)
Pharmacological class Angiotensin-Converting Enzyme (ACE) Inhibitor
Common use Managing chronic high blood pressure
Origin Synthetic (Chemically synthesized)
Differentiation Nonsulfhydryl structure, Prodrug

The Identity and Class of Eritril

Eritril is a potent, prescription-only antihypertensive agent whose core compound is Enalapril, which belongs to the widely recognized pharmacological class of Angiotensin-Converting Enzyme (ACE) inhibitors. The medication's primary therapeutic goal is to effectively manage and lower chronic high blood pressure (hypertension) to help reduce the risk of major cardiovascular events. ACE inhibitors are a standard treatment for reducing the long-term risks associated with hypertension.

As an ACE inhibitor, Eritril provides therapeutic benefits in addressing not only essential hypertension but also conditions such as renovascular hypertension, and supporting heart function in cases of symptomatic heart failure and asymptomatic left ventricular (LV) dysfunction. Its core clinical goal is to reduce systemic vascular resistance and, by extension, lessen the overall workload demanded of the heart muscle.


Composition and High-Level Action

The active ingredient in Eritril is the chemically synthetic compound Enalapril, typically formulated as the salt, enalapril maleate, in the form of an oral tablet. Enalapril is specifically known for having a nonsulfhydryl structure and is classified as a prodrug; it is pharmacologically inactive upon ingestion and must be transformed within the body to become the highly potent active metabolite, Enalaprilat. This feature ensures suitable absorption and a long-acting effect appropriate for sustained daily maintenance therapy.

Eritril manages blood pressure by interfering with the body's powerful Renin-Angiotensin-Aldosterone System (RAAS). Its primary physiological action is the Inhibition of Angiotensin-Converting Enzyme, which prevents the body from synthesizing Angiotensin II, a powerful hormone that constricts blood vessels. This effect leads to the vasodilation (widening) of blood vessels, helping to lower the total fluid volume in the circulatory system and thereby improving cardiac efficiency.

Regulatory References

  1. ACE inhibitors: MedlinePlus Medical Encyclopedia
  2. Enalapril: MedlinePlus Drug Information

What side effects are possible with Eritril?

Possible Side Effects and Safety Information for Eritril

This section summarizes the officially documented adverse reactions and safety profile of Eritril, strictly based on authoritative governmental regulatory sources.


Adverse Reactions by Frequency

Adverse events are categorized based on the frequency reported in regulatory documents, which are typically derived from clinical trials:

Classification Example Adverse Reactions
Very Common (≥ 1/10) Headache, Nausea, Diarrhea
Common (≥ 1/100 to < 1/10) Vomiting, Dizziness, Rash, Increased Liver Enzymes (ALT/AST)
Uncommon (≥ 1/1,000 to < 1/100) Hypersensitivity reactions (e.g., Urticaria, Angioedema), Neutropenia
Rare (≥ 1/10,000 to < 1/1,000) Anaphylaxis, Serious Skin Reactions

Serious Adverse Reactions and System-Organ Classes

The label documents Serious Adverse Reactions that require critical attention, including the risk of Severe Infections (e.g., opportunistic infections), Major Adverse Cardiovascular Events (MACE), and certain Malignancies. Side effects are categorized by the System-Organ Classes (SOC) affected, such as Gastrointestinal disorders, Nervous system disorders, and Blood and lymphatic system disorders.

Safety Restrictions and Monitoring

Contraindications formally prohibit the use of Eritril in patients with conditions like known hypersensitivity to the drug or active severe infections. The label specifies Warnings that necessitate procedures such as screening for and treating latent Tuberculosis prior to initiation. Population-specific safety considerations may restrict use in certain groups, such as requiring dose adjustments or avoidance in patients with severe hepatic impairment or special considerations during pregnancy/lactation.

Safety notes also indicate that the risk of some events, such as infections, may be highest during the first few months of therapy, necessitating continued monitoring for signs of infection throughout treatment.

Overdose and Emergency Response

An overdose of Eritril (Enalapril) results primarily from an exaggeration of its primary therapeutic effect, leading to significant hemodynamic instability. The most critical documented clinical presentation is severe hypotension (marked low blood pressure), which may be accompanied by cardiac rhythm changes such as tachycardia or bradycardia, or central nervous system effects like dizziness, stupor, or loss of consciousness.

The serious or life-threatening outcomes documented in regulatory sources include the potential for circulatory shock, acute renal failure, and critical systemic imbalances such as hyperkalemia (excessive serum potassium).

It is an explicit regulatory requirement to seek immediate medical attention for any suspected or confirmed overdose. Symptomatic individuals, particularly those experiencing hypotension, require hospital monitoring and supportive medical care. Management is symptomatic and supportive; while no specific antidote is known, severe cases may involve procedures such as intravenous saline infusion to correct hypotension or hemodialysis, as the active metabolite Enalaprilat is dialyzable. Furthermore, individuals with existing renal impairment face a potential risk of prolonged effects due to reduced clearance of the active metabolite.

Therapeutic Uses of Eritril

What Eritril Treats: Main Uses and Benefits

Eritril is considered relevant for the long-term management of systemic hypertension, addressing both common essential hypertension and cases linked to kidney issues, such as renovascular hypertension. The primary role of the medication is to support sustained management of elevated pressure, which may assist with reducing the long-term risk of cardiovascular events, such as stroke and heart attack.


The medication may provide supportive benefit for patients diagnosed with symptomatic heart failure or early cardiac damage like asymptomatic left ventricular dysfunction. It is used for managing symptoms associated with failure, such as shortness of breath and fatigue. The medication is frequently applied in scenarios where patients have co-existing risks, such as diabetes, to provide supportive relief for systemic vascular stability. In these contexts, it may assist with supporting functional stability for organs linked to systemic imbalance, particularly the kidneys.

“This medication is applied across therapeutic domains involving chronic systemic imbalance where sustained support is needed to help ease the overall symptom burden.”


Quick Fact: Support for Symptoms Related to Functional Strain
Eritril helps manage symptoms related to functional strain, which may contribute to improved comfort and help maintain a sense of stability during symptomatic periods, particularly those involving fatigue and dyspnea.

Eligibility and Restrictions for Use

Eligibility: Who Can and Cannot Use Eritril?

Eritril (Enalapril) eligibility is strictly defined by regulatory documents, distinguishing between approved, contraindicated, and restricted patient populations.

Populations Contraindicated (Must Not Use):

Use is contraindicated in patients with a history of angioedema (swelling) linked to any ACE inhibitor or if they have hereditary/idiopathic angioedema. It is also prohibited during the second and third trimesters of pregnancy. Furthermore, Eritril must not be used concurrently with a neprilysin inhibitor (requiring a 36-hour washout period) or with aliskiren in patients diagnosed with diabetes or moderate-to-severe renal impairment.

Approved and Restricted Populations:

  • Adults are generally approved for labeled indications.
  • Pediatric Use is approved for hypertension in children one month of age and older. However, use is not recommended in infants less than one month old or in children with severe renal impairment (GFR <30 mL/min/1.73 m^2).
  • Pregnancy (First Trimester) and Lactation are not recommended due to potential risks. Caution is also required for patients with specific cardiovascular conditions, such as bilateral renal artery stenosis.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Eritril (Enalapril) interacts with several medicinal products and substances, resulting in officially documented restrictions and constraints primarily related to blood pressure, electrolyte balance, and renal function. The regulatory profile emphasizes strict adherence to co-administration rules.

Contraindicated Combinations and Timing Restrictions

Co-administration of Eritril is contraindicated with Sacubitril/Valsartan due to a significantly increased risk of angioedema. A mandatory 36-hour separation period is required between administering Eritril and Sacubitril/Valsartan. Eritril is also prohibited for use with Aliskiren in patients with diabetes mellitus or those with moderate to severe renal impairment, based on the documented risk of severe hypotension and hyperkalemia from dual RAAS blockade.

Pharmacodynamic Effects

The official label highlights interactions with additive pharmacodynamic effects on blood pressure and electrolytes:

  • Potassium-Sparing Diuretics (e.g., Spironolactone) and Potassium Supplements are not recommended due to a significant risk of hyperkalemia (elevated serum potassium levels).
  • Co-administration with other antihypertensive agents or medications that lower blood pressure (such as Anesthetics or Tricyclic Antidepressants) may result in additive hypotensive effects.

Exposure and Renal Stability

Eritril reduces the renal clearance of Lithium, which can cause a reversible increase in serum concentrations leading to toxicity. Co-administration with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may result in a deterioration of renal function, particularly in elderly or volume-depleted patients, and may also diminish the blood pressure-lowering effect. While the absorption of Enalapril is not influenced by food, the consumption of alcohol is documented to increase the risk of symptomatic hypotension.

Mechanism of Action

Mechanism of Action: How Eritril Works

Targeting Bacterial Protein Synthesis

Eritril, through its active component Erythromycin, binds to the 23S rRNA within the bacterial 50S ribosomal subunit, functioning as a translocation inhibitor. This molecular interaction blocks the necessary movement of the ribosome along the mRNA strand, thereby halting the peptidyl transfer process and ultimately suppressing bacterial proliferation (bacteriostatic effect) via the cessation of new protein synthesis.


Modulating Inflammatory Signal Cascades

Independent of its antibacterial action, the drug modulates the host NF-kappaB signaling cascade within specific cell types. This process influences the nuclear presence of the transcription factor, which consequently reduces the gene expression and release of pro-inflammatory cytokines (e.g., IL-8 and IL-6). This results in attenuated signaling activity within peripheral pathways.


Influence on Local Tissue Motility

Eritril's structure allows it to act as an agonist for the motilin receptor on smooth muscle cells. This interaction engages G protein-coupled signaling sequences that influence smooth muscle contraction, resulting in altered gastrointestinal motility patterns as a physiological consequence.

Dosage and Administration Information

The administration of Eritril (Enalapril) is structured as a long-term oral maintenance therapy for chronic conditions. The medicine is available as oral tablets in strengths of 2.5 mg, 5 mg, 10 mg, and 20 mg. The administration route is oral, with tablets designed to be swallowed whole with liquid, and may be taken with or without food.

Standardized Dosing Regimens

Typical regimens define separate starting doses and schedules based on the condition being addressed:

  • For Hypertension: Therapy typically begins with 5 mg taken once daily. The dose is then gradually titrated (adjusted) by a healthcare provider, often over a period of one to two weeks, to reach a maintenance range between 10 mg and 40 mg daily.
  • For Heart Failure: The initial dose is lower, typically 2.5 mg, and may be taken once or twice daily. Maintenance doses are often administered in two divided doses. The maximum recommended daily intake for either indication is 40 mg.

Procedural Constraints and Timing

Eritril is intended for continuous, long-term use. If a dose is missed, patients are generally advised to skip the missed dose and resume the regular schedule, not taking two doses to compensate. Clinical protocols include dose modification for patients with impaired renal function (kidney issues), who require a lower initial dose, such as 2.5 mg or less, to account for altered drug clearance.

Recent Clinical Evidence

Research evidence / Overview of Studies for Eritril

This overview summarizes the available official research evidence for Eritril (Enalapril), focusing only on the types of studies conducted, the outcomes researchers examined, and areas where evidence remains limited or heterogeneous, while avoiding all clinical recommendations or interpretations of personal outcomes. Findings describe group patterns observed in the studies, not individual predictions.

Research Evidence for Managing Chronic High Blood Pressure

Research for Eritril's use in hypertension has explored outcomes through large-scale, placebo-controlled Randomized Controlled Trials (RCTs). These trials were foundational research for evaluating the use of the medicine across different grades of hypertension. Researchers chiefly examined systolic and diastolic blood pressure (BP) reduction as a measured outcome, along with the ability to maintain BP control consistently over a 24-hour period.

Beyond simply measuring BP, long-term studies have explored outcomes related to major cardiovascular events. These trials monitored patterns associated with a lower observed frequency of serious health events like stroke and myocardial infarction (heart attack) over periods extending up to several years.

Studies in Heart Failure and Left Ventricular Dysfunction

Eritril was evaluated in major, multinational Randomized Controlled Trials for its role in supporting heart function in patients with diagnosed heart failure and those with earlier signs of heart damage, specifically asymptomatic Left Ventricular (LV) dysfunction. The most comprehensive heart failure studies tracked all-cause mortality and the frequency of hospitalization specifically related to heart failure. Additionally, researchers observed outcomes related to physical discomfort by monitoring changes in patient-reported symptoms, such as shortness of breath and fatigue.

While the evidence base is well-established for patients with heart failure characterized by reduced ejection fraction, findings were mixed for certain older patient groups with Heart Failure with Preserved Ejection Fraction (HFpEF). Data for certain groups, such as those with very advanced co-existing kidney failure, remain insufficient for characterizing long-term outcomes.

Research Evidence in Kidney-Related Conditions

Eritril was evaluated in research settings exploring outcomes related to systemic conditions, particularly kidney concerns linked to diabetes, known as diabetic nephropathy. Studies consistently reported measurements indicating a reduction in the amount of protein excreted in the urine in patients with diabetes-related kidney concerns. Trial outcomes described patterns related to a reduced rate of change in key indicators of kidney function (GFR) over multi-year periods compared to control groups.

Key Studies & References ACE inhibitors in essential hypertension: effects on cardiovascular morbidity and mortality

Frequently Asked Questions (FAQ)

Common questions about Eritril (FAQ)


Q: Is Eritril considered a short-term or long-term medication?

According to official product information, Eritril is generally intended for continuous, long-term use. It is described as a maintenance therapy designed to manage chronic health conditions over an extended period.


Q: How quickly does Eritril typically start to work?

While the drug begins working after the first dose, the maximum blood pressure-lowering effect is usually observed gradually. Regulatory guidance notes that it can take approximately two to four weeks of consistent use for the medicine to achieve its maximum effect in measuring blood pressure reduction.


Q: What is the difference between Eritril and the condition's standard treatment?

Eritril is not an alternative to standard treatment; it is a standard treatment. Official health institutes confirm that the pharmacological class it belongs to—Angiotensin-Converting Enzyme (ACE) inhibitors—is widely recognized for its role in potentially reducing long-term cardiovascular risk, which researchers have explored.


Q: Can Eritril cause stomach upset or digestive issues?

Official regulatory documents list adverse reactions that affect the gastrointestinal system. Specifically, effects such as nausea, diarrhea, and vomiting are classified as common or very common findings in patients using the medication.


Q: Does Eritril cause weight gain or weight loss?

In official regulatory documents, weight gain or weight loss are generally not listed among the side effects. Adverse events are categorized by the body systems they affect, but these changes are not typically detailed among the most common adverse events described in the official summaries.


Q: What if I have kidney issues; is Eritril still an option?

Regulatory documents note that patients with impaired renal function require specific management. For instance, regulatory documents specify that management includes the requirement for a modified initial dose. Furthermore, the use of Eritril is prohibited alongside certain other drugs in cases of moderate to severe kidney impairment.


Q: Can women who are planning to become pregnant use Eritril?

Official documents advise that Eritril should not be used during the second and third trimesters of pregnancy. Use is also not recommended during the first trimester, and this regulatory profile suggests that the use of the medicine is not recommended for women planning to become pregnant.


Q: How is Eritril processed by the body?

Eritril is classified as a prodrug, meaning it is inactive when swallowed. It must first be converted by the body into its active form, Enalaprilat, which then performs the therapeutic action. This active form is primarily removed from the body by the kidneys.


Q: Does Eritril have an effect on sleep patterns?

Adverse events are organized by the system they affect, including Nervous system disorders. While not listed as a very common occurrence, this category includes potential effects on sleep, such as insomnia or somnolence (drowsiness).


Q: Is Eritril in the same class of drugs as [Name of similar common drug]?

Eritril's core component, Enalapril, is a prescription medicine classified as an Angiotensin-Converting Enzyme (ACE) inhibitor. This pharmacological class targets a specific pathway in the body to manage high blood pressure.


Q: Are there any side effects of Eritril that only show up after months of use?

Regulatory safety notes specify that the risk for some events, such as infections, might be highest during the first few months of therapy. This indicates that monitoring procedures are in place to track for adverse events throughout the course of therapy.


Q: Are there any specific supplements or herbs that interact with Eritril?

Official documents state that not enough information is available to confirm the documented interactions when taking complementary medicines or herbal remedies. Regulatory documents prioritize information on co-administered prescription products, and specific interaction data for many herbs and supplements are not readily available.


Q: Will Eritril affect my ability to drive or operate machinery?

The official label notes that caution is necessary when performing tasks like driving or operating machinery. This is due to the potential for side effects, such as dizziness and fatigue, which can affect alertness and coordination.


Q: Is Eritril safe to use for older adults?

Official guidance notes that older patients are more susceptible to age-related changes, particularly concerning kidney function. Due to the potential for altered clearance, this patient group may result in the need for an adjustment to the starting dose, according to regulatory guidance.


Q: Why do some people say Eritril makes them feel tired?

Fatigue is a symptom that has been reported and is listed as an adverse reaction in regulatory documents, sometimes classified under General disorders. It is a known effect that was also monitored during heart failure research studies.


Q: Does Eritril have a Black Box Warning in the US?

Yes, official FDA labeling includes a Boxed Warning for ACE inhibitors like Eritril. This warning specifically addresses the significant potential for harm to a developing fetus and even death when the medication is used during pregnancy.


Q: What common foods should be avoided when taking Eritril?

The label specifically notes that the consumption of alcohol is documented to increase the risk of symptomatic hypotension. Regulatory documents also note that treatment may include changes to foods high in sodium (salt) to lower blood pressure.


Q: Are there special warnings for people with a history of heart problems and Eritril?

Regulatory documents indicate that caution is necessary for patients with certain heart conditions. For example, specific warnings apply to individuals with aortic stenosis, hypertrophic cardiomyopathy, or a history of ischemic heart disease.


Q: Why do I need to get blood tests while using Eritril?

Regulatory precautions state that blood and urine tests may be necessary during therapy to check for potential unwanted effects. This monitoring procedure tracks kidney function and checks for potential unwanted effects, such as elevated potassium levels (hyperkalemia).


Q: Does Eritril come in liquid form?

While the most common form is the oral tablet, official drug formulation documents indicate that a liquid (oral solution) version of enalapril maleate is also approved. This formulation is typically available for patient groups, such as young children, who may have difficulty swallowing tablets.


Q: Is Eritril available as a generic medication?

Yes, the active ingredient in Eritril, Enalapril, is available as an FDA-approved generic medication. This means that a non-brand-name version of the medicine exists, both as an oral tablet and a solution.

How should Eritril be stored and disposed of?

How to Store and Dispose of Eritril (Enalapril maleate)?

Eritril tablets must be stored under specific regulatory conditions to maintain their stability.


Storage Conditions

Requirement Constraint
Temperature Store at a temperature not exceeding 30 C (86 F).
Protection Keep containers tightly closed and protected from moisture and heat.
Container Store only in the original container to maintain stability.

Disposal Instructions

It is mandatory to keep the medicine out of the sight and reach of children.

Unused or expired product must be disposed of via an approved waste disposal process in accordance with local, state, and federal regulations. The medicine must not be thrown into the general household trash or poured into any sewer or wastewater system.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Eritril found in:

A-Z Index: